Medizinische Universität Graz - Research portal

Navigation/Search

• Researchers.
• Institutions.
  • Address and mission.
  • Equipment/Knowhow.
  • Staff.
  • Projects.
  • Publications.
  • Advised theses.
  • Project partners.
  • Sponsors.
• Projects.
• Publications.
• Partners.
• Sponsors.
• Equipment.
• Knowhow.
• Fields of Research.

Clinical Institute of Medical and Chemical Laboratory Diagnostics

Project partners

Medizinische Universität Innsbruck (MUI), Innsbruck, Austria

VEGF-polymorphisms and breast cancer risk
• Project type: EN: Forschungsförderung.
• Project Leader: Langsenlehner Uwe
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ; Department of Radiology ; Department of Therapeutic Radiology and Oncology ; Division of Oncology ;
• Funded by: Österreichische Nationalbank (Jubiläumsfonds), Otto Wagner Platz 3, A-1090 Wien, Austria
• Programme: Jubiläumsfonds (ÖNB)
• Duration: 01.01.2004-31.07.2005
   .

Analysis of four genetic polymorphisms of integrins and their association with breast cancer risk and progression
• Project type: EN: Forschungsförderung.
• Project Leader: Langsenlehner Uwe
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ; Department of Radiology ; Department of Therapeutic Radiology and Oncology ; Division of Oncology ;
• Funded by: Österreichische Krebshilfe Steiermark, Rudolf-Hans-Bartsch-Straße 15-17, 8042 Graz, Austria
• Duration: 15.10.2004-14.10.2005
   .

Universität für Bodenkultur Wien, Gregor Mendel Straße 33, 1180 Wien, Austria

The influence of neuroblastoma and its chemotherapy on gut barrier, inflammation and metabolism.
• Project type: EN: Forschungsförderung.
• Project Leader: Castellani Christoph
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ; Department of Biomedical Research ; Department of Paediatric and Adolescent Surgery ; Department of Paediatrics and Adolescent Medicine ; Diagnostic and Research Institute of Pathology ;
• Funded by: MEFOgraz , Neue Stiftingtalstraße 6 WEST, 8010 Graz, Austria Monika Kutzner Stiftung, Bayerische Straße 8, 10707 Berlin-Wilmersdorf, Germany
• Duration: 01.01.2017-31.03.2018
   .

Department of Orthopaedic Surgery/Medical University Sofia , 15 Dimitar Nestorov Street, 1431 Sofia, Bulgaria

Modulatory Effect of Antioxidants on the Oxidative Stress of Stimulated Macrophages
• Project type: EN: Forschungsförderung.
• Project Leader: Windhager Reinhard
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ; Department of Orthopaedics and Trauma ; Diagnostic and Research Institute of Pathology ; Division of Cell Biology, Histology and Embryology ; Division of Immunology ;
• Funded by: Österreichische Nationalbank (Jubiläumsfonds), Otto Wagner Platz 3, A-1090 Wien, Austria
• Programme: Jubiläumsfonds (ÖNB)
• Duration: 01.07.2006-30.06.2008
   .

Odense Universitetshospital, Odense, Denmark

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

Assistance Publique - Hopitaux de Paris, 3 Avenue Victoria, 75004 Paris, France

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

Commissariat a l´Energie Atomique et aux Energies Alternatives, France

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

INSERM, France

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

Inserm-Transfert, France

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

Max-Planck-Gesellschaft, Berlin, Germany

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

NanoPET Pharma, Robert-Koch-Platz 4, 10115 Berlin , Germany

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

University of Erlangen, angen, Germany

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

Semmelweis University Budapest, Budapest, Hungary

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

WizSoft, Beit Hillel 3, 67017 Tel Aviv-Jaffo, Israel

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

Bracco Imaging SpA, Via Egidio Folli 50, 20134 Milan, Italy

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

University of Twente, Twente, Netherlands

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

VU University Medical Center, Amsterdam, Netherlands

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

Edinethics, 11/6 DUNDONALD STREET, EH3 6RZ Edingburgh, United Kingdom

Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
• Project type: EN: Forschungsförderung.
• Project Leader: Mangge Harald
• MUG Research Units: Clinical Institute of Medical and Chemical Laboratory Diagnostics ;
• Funded by: Europäische Kommission, Rue de la Loi, Brussels, Belgium
• Programme: EU (FP-7)
• Duration: 01.02.2013-31.01.2018
   .

↑ Top of page / Navigation

© Med Uni Graz • Imprint